Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 176

2.

Vasopressin and the Regulation of Thirst.

Bichet DG.

Ann Nutr Metab. 2018;72 Suppl 2:3-7. doi: 10.1159/000488233. Epub 2018 Jun 20.

3.

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.

Schiffmann R, Bichet DG, Jovanovic A, Hughes DA, Giugliani R, Feldt-Rasmussen U, Shankar SP, Barisoni L, Colvin RB, Jennette JC, Holdbrook F, Mulberg A, Castelli JP, Skuban N, Barth JA, Nicholls K.

Orphanet J Rare Dis. 2018 Apr 27;13(1):68. doi: 10.1186/s13023-018-0813-7.

4.

Analysis of globotriaosylceramide (Gb3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry.

Toupin A, Lavoie P, Arthus MF, Abaoui M, Boutin M, Fortier C, Ménard C, Bichet DG, Auray-Blais C.

Anal Chim Acta. 2018 Jul 26;1015:35-49. doi: 10.1016/j.aca.2018.02.022. Epub 2018 Feb 19.

PMID:
29530250
5.

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM.

J Med Genet. 2018 May;55(5):351-358. doi: 10.1136/jmedgenet-2017-104863. Epub 2018 Feb 7.

6.

Mice deficient for ERAD machinery component Sel1L develop central diabetes insipidus.

Bichet DG, Lussier Y.

J Clin Invest. 2017 Oct 2;127(10):3591-3593. doi: 10.1172/JCI96839. Epub 2017 Sep 18.

7.

Vasopressin: physiology, assessment and osmosensation.

Bankir L, Bichet DG, Morgenthaler NG.

J Intern Med. 2017 Oct;282(4):284-297. doi: 10.1111/joim.12645. Epub 2017 Jul 26. Review.

PMID:
28649750
8.

Hepatocyte Nuclear Factor-1β Regulates Urinary Concentration and Response to Hypertonicity.

Aboudehen K, Noureddine L, Cobo-Stark P, Avdulov S, Farahani S, Gearhart MD, Bichet DG, Pontoglio M, Patel V, Igarashi P.

J Am Soc Nephrol. 2017 Oct;28(10):2887-2900. doi: 10.1681/ASN.2016101095. Epub 2017 May 15.

PMID:
28507058
9.

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.

Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, McFarlane P, Pandeya S, Tam P, Bichet DG.

Can J Kidney Health Dis. 2017 Mar 1;4:2054358117695784. doi: 10.1177/2054358117695784. eCollection 2017.

10.

Nephrogenic diabetes insipidus.

Bockenhauer D, Bichet DG.

Curr Opin Pediatr. 2017 Apr;29(2):199-205. doi: 10.1097/MOP.0000000000000473. Review.

PMID:
28134709
11.

Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors.

Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N.

Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E127-E135. doi: 10.1152/ajpendo.00269.2016. Epub 2016 Dec 20.

12.

Impaired Left Atrial Function in Fabry Disease: A Longitudinal Speckle-Tracking Echocardiography Study.

Pichette M, Serri K, Pagé M, Di LZ, Bichet DG, Poulin F.

J Am Soc Echocardiogr. 2017 Feb;30(2):170-179.e2. doi: 10.1016/j.echo.2016.10.014. Epub 2016 Dec 6.

PMID:
27939050
13.

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U.

J Med Genet. 2017 Apr;54(4):288-296. doi: 10.1136/jmedgenet-2016-104178. Epub 2016 Nov 10. Erratum in: J Med Genet. 2018 Apr 16;:.

14.

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ.

Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22.

15.

Functional Recovery of AQP2 Recessive Mutations Through Hetero-Oligomerization with Wild-Type Counterpart.

El Tarazi A, Lussier Y, Da Cal S, Bissonnette P, Bichet DG.

Sci Rep. 2016 Sep 19;6:33298. doi: 10.1038/srep33298.

16.
17.

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R.

N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.

18.

Vasopressin at Central Levels and Consequences of Dehydration.

Bichet DG.

Ann Nutr Metab. 2016;68 Suppl 2:19-23. doi: 10.1159/000446200. Epub 2016 Jun 16.

19.

MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2.

Coady MJ, El Tarazi A, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY.

J Am Soc Nephrol. 2017 Jan;28(1):85-93. doi: 10.1681/ASN.2015111282. Epub 2016 Jun 10.

20.

Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).

Bichet DG, Bockenhauer D.

Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):263-76. doi: 10.1016/j.beem.2016.02.010. Epub 2016 Mar 2. Review.

PMID:
27156763

Supplemental Content

Loading ...
Support Center